Northern Trust Corp Has $1.11 Million Position in ProQR Therapeutics (NASDAQ:PRQR)

Northern Trust Corp raised its position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 2,550.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 417,398 shares of the biopharmaceutical company's stock after purchasing an additional 401,648 shares during the quarter. Northern Trust Corp owned approximately 0.51% of ProQR Therapeutics worth $1,106,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Affinity Asset Advisors LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $7,486,000. M&T Bank Corp bought a new position in ProQR Therapeutics during the fourth quarter valued at approximately $330,000. XTX Topco Ltd acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $163,000. Altium Capital Management LLC bought a new stake in ProQR Therapeutics in the fourth quarter worth approximately $1,524,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of ProQR Therapeutics by 164.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock worth $25,446,000 after purchasing an additional 5,976,813 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 price objective for the company. Oppenheimer reduced their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. HC Wainwright upped their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, March 14th. Evercore ISI assumed coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price objective on the stock. Finally, Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, ProQR Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR traded down $0.06 during trading hours on Friday, hitting $1.68. 271,509 shares of the company's stock were exchanged, compared to its average volume of 634,174. The company's 50-day moving average price is $1.47 and its 200-day moving average price is $2.22. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62. The stock has a market capitalization of $176.76 million, a price-to-earnings ratio of -5.25 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.90 million. On average, research analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).